Table 2A. Outcome after 177Lu-prostate-specific membrane antigen (LuPSMA) radioligand therapy for patients with LNM with or without one or two bone metastases.
| Outcomes | Presence of one or two bone metastases | p-value | |
|---|---|---|---|
| No (n = 35) | Yes (n = 10) | ||
| Maximum percentile decline of PSA (%, median IQR) | 0.94 (0.74–0.99) | 0.54 (–0.09–0.96) | 0.016 |
| Median PSA PFS (mo) | 17 | 7 | 0.21 |
| Median PSMA PET/CT PFS (mo) | 27 | 13 | 0.35 |
| Median OS (mo) | NR | 42 | 0.046 |
Abbreviations: IQR, interquartile range; mo, months; NR, not reached; OS, overall survival; PFS, progression-free survival; PSA, prostate specific antigen; PSMA, prostate specific membrane antigen. The p-values were based on t tests.